Literature DB >> 6254639

Phase I study of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466) in adults with solid tumors.

D J Stewart, R S Benjamin, M Leavens, M Valdivieso, M A Burgess, G P Bodey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254639

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  5 in total

1.  Intracarotid infusion of PCNU (NSC: 95466): preclinical toxicological study in dogs.

Authors:  L Goumnerova; M T Richard; D Addison; V Montpetit; D J Stewart
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study.

Authors:  R H Earhart; F M Muggia; F M Golomb
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.

Authors:  B Drewinko; L Y Yang
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Phase I study of intracarotid PCNU.

Authors:  D J Stewart; Z Grahovac; N A Russel; H Hugenholtz; S Gupta; B C Benoit; M T Richard; J A Maroun; H S Hopkins; L Locke
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

5.  Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A.

Authors:  E M Hiesiger; S B Green; W R Shapiro; P C Burger; R G Selker; M S Mahaley; J Ransohoff; J C VanGilder; J Mealey; J T Robertson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.